Is NS - 500 Sodium Chloride BP Infusion registered in Zambia?

NS - 500 Sodium Chloride BP Infusion is recorded with registration status “Registered/Compliant” in Zambia, registration number 316/002, based on ZAMRA data.

Who manufactures NS - 500 Sodium Chloride BP Infusion?

NS - 500 Sodium Chloride BP Infusion is manufactured by Abacus Parenteral Drugs.

What is the active ingredient in NS - 500 Sodium Chloride BP Infusion?

NS - 500 Sodium Chloride BP Infusion contains Sodium Chloride Intravenous Infusion BP 0.9% w/v, dosage form solution for IV injection.

Registered Zambia · ZAMRA

NS 500 Sodium Chloride BP Infusion

Sodium Chloride Intravenous Infusion BP 0.9% w/v

316/002 solution for IV injection

What it does

Intravenous (IV) therapy involves delivering medications or fluids directly into the bloodstream through a vein.

Commonly used for: dehydration, infections, surgery recovery, pain management …

Registration & product details

Registration no.

316/002

Registration date

2024-10-16

Expiry date

2029-10-15

Status

Registered/Compliant

Active ingredient

Sodium Chloride Intravenous Infusion BP 0.9% w/v

Dosage form

solution for IV injection

Strength

Pack size

Therapeutic class

Manufacturer / MAH

Abacus Parenteral Drugs

Applicant / LTR

Abacus Parenteral Drugs Ltd (APDL)

Country of origin

Uganda

Manufacturer location

Jinja Kampala Road, Mukono, Uganda

Source: Zambia Medicines Regulatory Authority · fetched 2026-03-12 00:04:50 · updated 2026-09-24 03:36:56

Disclaimer: This information is sourced from Zambia Medicines Regulatory Authority (Zambia). Always consult a qualified healthcare professional before using any medication.

About this medicine

Intravenous (IV) therapy involves delivering medications or fluids directly into the bloodstream through a vein.

What it treats

dehydration
infections
surgery recovery
pain management
nutrition support

How it works

IV therapy allows quick delivery of fluids and medications, helping to treat various conditions effectively.

Who it's for

IV therapy is suitable for patients who cannot take medications by mouth or need immediate treatment.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: intravenous

Intravenous (IV) administration refers to the delivery of substances directly into the bloodstream through a vein. This method is commonly used for the rapid delivery of medications, fluids, and nutrients, allowing for immediate systemic effects. IV administration is vital in emergency situations, surgical procedures, and for patients who cannot take medications orally.

Indications

Dehydration
Electrolyte imbalances
Infections requiring immediate antibiotic therapy
Pain management in acute settings
Nutritional support in patients unable to eat
Chemotherapy administration
Anesthesia induction and maintenance

Dosage

Children: Refer to the specific drug's prescribing information in the BNF for Children for appropriate dosing guidelines.

Adults: Refer to the specific drug's prescribing information in the BNF for appropriate dosing guidelines.

Mechanism of action

The mechanism of action for intravenous drugs depends on the specific medication administered. Generally, intravenous administration allows for rapid drug distribution throughout the body, achieving high plasma concentrations quickly. This is particularly beneficial for medications that require immediate therapeutic effects.

Pharmacodynamics

Pharmacodynamics varies based on the specific drug administered intravenously. In general, drugs delivered via IV can achieve peak plasma concentrations faster than those taken orally, leading to quicker onset of action. This route is often utilized for drugs that are poorly absorbed in the gastrointestinal tract or for those that require precise titration to achieve the desired therapeutic effect.

Pharmacokinetics

Pharmacokinetics for intravenous drugs typically includes immediate bioavailability since the drug is delivered directly into circulation. Distribution is rapid, and elimination depends on the drug's specific metabolic pathways. Volume of distribution, clearance rates, and half-life can significantly vary based on the drug's properties and patient factors such as age, body weight, and organ function.

Interactions

ataluren + intravenous aminoglycosides: Severe (increases risk of nephrotoxicity)
intravenous dantrolene + calcium channel blockers: Severe (increases risk of acute hyperkalaemia and cardiovascular collapse)
intravenous dantrolene + diltiazem: Severe (increases risk of acute hyperkalaemia and cardiovascular collapse)
intravenous dantrolene + verapamil: Severe (increases risk of acute hyperkalaemia and cardiovascular collapse)
intravenous chloramphenicol + antiepileptics: Moderate (increases concentration)
intravenous chloramphenicol + fosphenytoin: Moderate (increases concentration)
intravenous chloramphenicol + phenytoin: Moderate (increases concentration)
miconazole + intravenous benzodiazepines: Moderate (increases exposure)
intravenous magnesium + calcium channel blockers: Unknown (increases risk of hypotension)
intravenous magnesium + amlodipine: Unknown (increases risk of hypotension)

PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.